AnaptysBio (ANAB) CMO sells shares to cover RSU vesting

Rhea-AI Filing Summary

AnaptysBio Chief Medical Officer Paul F. Lizzul reported routine equity activity. On January 7, 2026, 8,525 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, reflecting scheduled vesting. The RSU award is set to vest 25% per year starting January 7, 2026, as long as he continues providing services.

On January 8, 2026, he sold 3,650 shares of AnaptysBio common stock at $44.71 per share. The footnotes state this was a “sell to cover” transaction to satisfy tax withholding obligations tied to the RSU vesting, and was not a discretionary sale. After these transactions, he directly held 42,088 shares of common stock and 25,575 RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lizzul Paul F.

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		M		8,525	A	(1)	45,738	D
Common Stock	01/08/2026		S(2)		3,650	D	$44.71	42,088	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/07/2026		M			8,525	(3)	(3)	Common Stock	8,525	$0	25,575	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

3. The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did AnaptysBio (ANAB) report in this Form 4?

The filing shows Chief Medical Officer Paul F. Lizzul had 8,525 RSUs convert into common stock on January 7, 2026, and sold 3,650 shares on January 8, 2026.

Why did the AnaptysBio CMO sell 3,650 shares of ANAB stock?

The filing explains the 3,650-share sale at $44.71 per share was to cover tax withholding obligations from RSU vesting through a “sell to cover” transaction, not a discretionary sale.

How many AnaptysBio RSUs vested for the CMO in this filing?

On January 7, 2026, 8,525 RSUs vested and were settled into 8,525 shares of AnaptysBio common stock for no cash consideration.

What is the AnaptysBio CMO’s remaining equity position after these transactions?

After the reported transactions, he directly held 42,088 shares of common stock and 25,575 RSUs, according to the ownership columns.

How do the AnaptysBio RSUs for the CMO vest over time?

The RSUs vest as to 25% of the total grant each year starting on January 7, 2026, until fully vested, subject to his continued service to AnaptysBio on each vesting date.

What does each AnaptysBio RSU represent for the CMO?

Each RSU represents a contingent right to receive 1 share of AnaptysBio common stock upon settlement for no cash consideration.